On the stock market since 2017, it operates in the world of health and science. It has 55 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 92% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 135% a year on average.
The company sells $874.9M a year; the problem isn’t sales — it’s costs running above that number.
A loss of $5.1B against $874.9M in annual sales.
The stock sits at $0.36. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, AMGXF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: AMGXF has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.